Sarcopenia and sarcopenic obesity in cardiovascular disease: a comprehensive review

Sarcopenia is the loss of muscle strength, mass and function. It is often exacerbated by chronic comorbidities such as cardiovascular diseases (CVDs). There is a bidirectional relationship between sarcopenia and CVD. Sarcopenia can lead to increased adiposity, insulin resistance and chronic inflammation, predisposing adults to developing cardiovascular events. Chronic inflammation and decreased physical activity observed in cardiac patients can lead to accelerated muscle loss and the development of sarcopenia. Sarcopenia is linked to faster CVD progression, higher mortality and reduced quality of life. The co-occurrence of obesity with sarcopenia is termed sarcopenic obesity (SO). This condition is associated with worse outcomes than either condition individually. Early detection is crucial, as interventions can slow or reverse sarcopenia and improve cardiovascular outcomes. This review summarises evidence on the interplay between CVD and sarcopenia, discusses diagnostic approaches and management strategies, and identifies knowledge gaps for future research.